Anti-invasive and anti-angiogenic compositions

Details Anti-invasive and anti-angiogenic compositions Anti-invasive and anti-angiogenic compositions

2006-11-15

2010-10-05

Helms, Larry R. (Department: 1642)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C424S184100, C424S093100

Reexamination Certificate

active

07807621

ABSTRACT:
A peptide compound having the sequence Lys-Pro-Ser-Ser-Pro-Pro-Glu-Glu [SEQ ID NO:2] or a substitution variant, addition variant or other chemical derivative thereof inhibits cell invasion, endothelial tube formation or angiogenesis in vitro. A number of substitution variants and addition variants of this peptide, preferably capped at the N- and C-termini, as well as peptidomimetic derivatives, are useful for treating diseases and conditions mediated by undesired and uncontrolled cell invasion and/or angiogenesis. Pharmaceutical compositions comprising the above peptides and derivatives are administered to subjects in need of such treatment in a dosage sufficient to inhibit invasion and/or angiogenesis. The disclosed compositions and methods are particularly useful for suppressing the growth and metastasis of tumors.

REFERENCES:
patent: 5073626 (1991-12-01), Wun et al.
patent: 5382514 (1995-01-01), Passaniti et al.
patent: 5409700 (1995-04-01), Heim et al.
patent: 5422090 (1995-06-01), Stephens et al.
patent: 5444153 (1995-08-01), Goss et al.
patent: 5470970 (1995-11-01), Sager et al.
patent: 5656726 (1997-08-01), Rosenberg et al.
patent: 6509445 (2003-01-01), Kobayashi et al.
patent: 238275 (1987-09-01), None
patent: 2 246 779 (1992-02-01), None
patent: WO 90/12091 (1990-10-01), None
patent: WO 90/12872 (1990-11-01), None
patent: WO 91/02057 (1991-02-01), None
patent: WO 92/02553 (1992-02-01), None
patent: WO 93/24141 (1993-12-01), None
patent: WO 94/28014 (1994-12-01), None
patent: WO 94/28145 (1994-12-01), None
patent: WO 95/02413 (1995-01-01), None
patent: WO 96/03414 (1996-02-01), None
patent: WO 97/05257 (1997-02-01), None
patent: WO 97/25422 (1997-07-01), None
patent: WO9725422 (1997-07-01), None
Kobayashi et al, Cancer Res. vol. 54, p. 844-849, 1994.
Sequence search result and Cowan et al Brain Res. 509, 1-7, 1990, abstract.
search result (Kobayashi), 2009.
Appella et al., “The Receptor-binding Sequence of Urokinase,”J. of Biol. chem.262:4437-4440 (1987).
Baker et al., “Inhibition of Cancer Cell Urokinase Plasminogen Activator by its Specific Inhibitor PA1-2 and Subsequent Effects on Extracellular Matrix Degradation,”Cancer Res.50:4676-4684 (1990).
Berkenblit et al., “Å6, a Urokinse Plasminogen Activator (uPA)-derived Peptide in Pateitns with Advanced Cynecologic Cancer: A Phase 1 Trial,”Gynecol. Oncol.99:50-57 (2005).
Billstrom et al., “The Urokinase Inhibitor p-Aminobenzamidine Inhibits Growth of a Human Prostate Tumor in SCID Mice,”Int. J. Cancer61:542-547 (1995).
Blasi et al., “The Receptor for Urokinase-Plasminogen Activator, Urokinase,”J. Cell Biochem32:179-186 (1986).
Blasi et al., “Urokinas-Type Plasminogen Activator: Proenzyme, Receptor, and Inhibitors,”J. Cell. Biol.104:801-804 (1987).
Blasi, A Surface Receptor for Urokinase Plasminogen Activator: a Link Between the Cytoskeleton and the Extracellulor Matrix,Protoplasma145:95-98 (1988).
Boyd et al., “A Urokinase-derived Peptide (Å6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis,”Am. J. Pathol.162:619-26 (2003).
Brynestad et al., “Influence of Peptide Acylation, Liposome Incorporation, and Synthetic Immunomodulators on the Immunogenicity of a 1-23 Peptide of Glycoprotein D of Herpes Simplex Virus: Implications of Subunit Vaccines,”J. Virol.64:680-685 (1990).
Chamers et al., “Macrophage Colony-stimulating Factor Mediates Invasion of Ovarian Cancer Cells through Urokinase,”Cancer Res.55:1578-1585 (1995).
Chucholowski et al., “Flow Cytofluorometric Analysis of the Urokinase Receptor (uPAR) on Tumor Cells by Fluorescent uPA-ligang or Monoclonal Antibody #3936,”Fibrinolysis6:Suppl. 4, 95-102 (1992).
Claeson, G., “Synthetic peptides and Peptidomimetics as substrates and inhibitors of trhombin and other proteases in the blood coagulation system,”Blood Coagul. Fibrinolysis5:411-436 (1994).
Dang et al., “Butyrate Affects the Expression of the Urokinase Plasminogen Activator (uPA) and its Receptor (Upar) Genes in Colon Cancer Cells,”Gastroenterology106:4, part 2, A380 (1994).
Dano et al. “Plasminoen Activators, Tissue Degradation, and Cancer,”Adv. Cancer Res.44:139-145, 202-209, and 236-239 (1985).
deVries et al., “Plasminogen Activators, Their Inhibitors, and Urokinase Receptor Emerge in Late Stages of Melanocytic Tumor Progression,”Am. J. of Path.144:70-81 (1994).
Duggan et al., “Urokinase Plasminogen Activator and Urokinase Plasminogen Activator Receipt in Breast Cancer,”Int. J. Cancer61:597-600 (1995).
Ellis et al., “Plasminogen Activation Initiated by Single-chain Urokinase-type Plasminogen Activator,”J. of Biol. Chem.264:2185-2188 (1989).
Evans et al., “Suppression of Pulmonary Metastases of Rat Mammary Cancer by Recombinant Urokinase Plasminogen Activator Inhibitor,”Am. Surg.61:692-697 (1995).
Fishman et al., Autocrine Regulation of Growth Stimulationin Human Epithelial Ovarian Carcinoma by serine-protease-catalysed Release of the Urinary-type Plasminogen-activator N-terminal Fragment,Biochem. J.341:765-769 (1999).
Geiger et al., “Inhibition of Urokinase (uPA) by Purified Protein C Inhibitor (PCI) on Human Epithelial Kidney Tumor Cells (TCL 598),”Thromb. Haemost.62:758 (1989).
Guo et al., “A Peptide Derived from the Nonreceptor Binding Region of Urokinase Plasminogen Activator (UPA) Inhibits Tumor Progresion and Angiogenesis and Induces Tumor Cell Death In Vivo,”FASEB J.14:1400-1410 (2000).
Guo et al., “An Antiangiogenic Urokinase Derived Peptide (Å6) Combined with Tamoxifen (TAM) Decreases Tumor Growth and Metastasis in a Synergeneic Model of Breast Cancer,”Cancer Res.62:4678-4684 (2002).
Gyetko et al., “Function of the Urokinase Receptor (CD87) in Neutrophil Chemotaxis,”J. Leukoc. Biol.58:533-538 (1995).
Henderson et la., “Transcriptional and Posttranscriptional Activating of Urokinase Plasminogen Activator Gene Expression in Metastatic Tumor Cells,”Cancer Res.52:2489-2496 (1992).
Hoosein et al., “Involvement of Urokinase and its Receptor in the Invasiveness of Human prostatic Carcinoma Cell Lines,”Cancer Commun.3:255-264 (1991).
Hruby, V.J., “Conformational and Topographical Considerations in the Design of Biologically Active Peptides,”Biopolymers33:1073-1082 (1993).
Hubbard et al., “Disregulation of Urokinase Plasminogen Activator Gene in Breast Cancer,”Eur. J. Canc.31A:103-107 (1995).
Janicke et al., “Urokinase-type Plasminogen Activator Antigen and Early Relapse in Breast Cancer,”The LancetII:8670, 1049 (1989).
Janicke et al., “Randomized Adjuvant Chemotherapy Trial in High-risk, Lymph Node-negative Breast Cancer Patients Identified by Urokinase-type Plasminogen Actiavtor and Plasminogen Activator Inhibitor Type 1,”J. Natl. Cancer Inst.93:913-920 (2001).
Jankun, “The Urokinase Plasminogen Activator Pathway as a Novel Mechanism of Tumor Targeting and Cell Membrane Traversal,”J. of Cell. Biochem.S17C:33, H242 (1993).
Jankun et al, “Expression and Localization of Elements of the Plasminogen Activation System in Benign Breast Disease and Breast Cancers,”J. Cell Biochem.53:135-144 (1993).
Kempf, D.J., “Design of Symmetry-Based Peptidomimetic Inhibitors of Human Immunodeficiency Virus Protease,”Meth. Enzymol.241:334-354 (1994).
Konecny et al., Association of Urokinase-type Plasminogen Activator and its Inhibitor with Disease Progression and Prognosis in Ovarian Cancer,Clin. Cancer Res.7:1743-1749 (2001).
Liu et al., “The inhibition of fibrin stimulated t-PA-induced plasminogen activation by the A Chain fragment 149-157 or urokinase,” see pp. 810-811, esp. table 1, Smith, E.A., “Peptides, chemistry and biology, Proceedings 13th APS, 1991 Cambridge” 1992 ESCOM, LEIDEN XP002083073.
McCabe et al.,

Affiliated with

Also associated with

Rating

Anti-invasive and anti-angiogenic compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-invasive and anti-angiogenic compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-invasive and anti-angiogenic compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4163432